This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actis Biologics, Inc.
Drug Names(s): RPI.4610, anti-FLT-1 ribozyme
Description: ANGIOZYME is a ribozyme that targets the high affinity receptor for Vascular Endothelial Growth Factor (VEGF) which is implicated in angiogenesis. ANGIOZYME is designed to decrease VEGF signaling and in that manner, decrease the growth of new blood vessels to tumors, hopefully preventing the spread of cancer.
Deal Structure: Angiozyme was a registered trademark of Ribozyme Pharmaceuticals, which later became Sirna Therapeutics. Development and commercialization of Angiozyme was being done in partnership with Chiron Corporation.
In September 2005, Actis Biologics received worldwide licensing for Angiozyme from Sirna and Chiron.
In April 2006, Chiron Corporation was acquired by Novartis.
In October 2006, Sirna Therapeutics was acquired by Merck.
Partners: Novartis AG Merck & Co., Inc.
Additional information available to subscribers only: